Comparing effect of Dexmedetomidine and Labetalol on Intraoperative blood loss and surgical field quality in Rhinoplasty: A double-Blinded Clinical Trial

Determining the effect of dexmedetomidine and labetolol on the amount of bleeding and transparency of the operation field during rhinoplasty surgery

A parallel-group, single-blind, randomized, phase 3 clinical trial on 40 patients. A lottery will be used for randomization.

All people aged 17-40 years who underwent primary rhinoplasty surgery in Moradi Rafsanjan Hospital in 1401 will be included in the study. Subjects are randomly assigned to two groups a) Dexmedetomidine b) Labtolol. Systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, before induction of anesthesia and 20 minutes after induction of anesthesia (before the start of stoma) and during the stoma stage will be measured using a sphygmomanometer and pulse oximeter and will be entered in the study checklist.

Consent to participate in the study, age 17-40 years, being in anesthesia class I (patients with normal health who do not have any systemic problems such as cardiac, vascular, respiratory, or endocrine problems), no history of known heart disease

Intervention group 1: They will receive dexmedetomidine at the rate of half to one microgram per kilogram of weight in the form of infusion at the same time as the operation begins. Intervention group 2: They will receive Labetolol in bolus injection form in the required amount (5-20 mg) intravenously during surgery.

Systolic blood pressure, diastolic blood pressure, heart rate, blood gas number, bleeding rate, blood weight removed from bleeding, satisfaction

After entering the operating room, people will be placed in study groups by lottery. Numbers 1 and 2 are written on a piece of paper and placed in sealed envelopes. The first patient will open the first envelope. If the number 1 comes out of the envelope, it is placed in the dexmedetomidine group, and of course the second person is placed in the labetalol group, and if the number 2 comes out, it is placed in the labetalol group, and the next person is placed in the dexmedetomidine group, and this process will continue until the end of the study.

In this study, the project partner who evaluates the hemodynamic indicators does not know about the grouping of people. Also, the data analyst does not know about the grouping of people and the data will be provided to him as a number.

All data is potentially shareable after de-identifying individuals

The access period starts 6 months after the results are published

Researchers working in academic and scientific institutions

Commitment to the principle of fiduciary

Sending an official letter to the Research Vice-Chancellor of Rafsanjan University of Medical Sciences

After the approval of the research vice-chancellor of Rafsanjan University of Medical Sciences, the data will be provided to the applicant.